Literature DB >> 17671826

Cytomegalovirus reactivation after low-dose steroid treatment for hemolytic anemia in a patient with primary Epstein-Barr virus infection.

Biserka Troselj-Vukic1, Irena Milotic, Franko Milotic, Marija Crnic-Martinovic, Blazenka Grahovac.   

Abstract

Cytomegalovirus reactivation is a well described event occurring after intensive therapeutic suppression of the immune function in patients with latent infection. Treatment protocols for suppression of the immune response often include high-dose steroids. However, it is not known whether even a low-dose steroid treatment can reactivate latent cytomegalovirus in otherwise healthy persons. We documented cytomegalovirus reactivation after low-dose steroid treatment for autoimmune hemolytic anemia as a complication of Epstein-Barr virus mononucleosis in an immunocompetent 21-year-old man.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17671826     DOI： 10.1007/s00508-007-0821-4

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


  13 in total

Review 1.  Acute complications of Epstein-Barr virus infectious mononucleosis.

Authors:  H B Jenson
Journal:  Curr Opin Pediatr       Date:  2000-06       Impact factor: 2.856

Review 2.  Epstein-Barr virus-recent advances.

Authors:  Karen F Macsween; Dorothy H Crawford
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

3.  Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.

Authors:  Lorne N Small; Joseph Lau; David R Snydman
Journal:  Clin Infect Dis       Date:  2006-08-23       Impact factor: 9.079

4.  HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation.

Authors:  Maiju Härmä; Krister Höckerstedt; Outi Lyytikäinen; Irmeli Lautenschlager
Journal:  J Med Virol       Date:  2006-06       Impact factor: 2.327

5.  Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG).

Authors:  A F Hassan-Walker; I M Kidd; C Sabin; P Sweny; P D Griffiths; V C Emery
Journal:  J Med Virol       Date:  1999-06       Impact factor: 2.327

6.  Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia.

Authors:  Yoshiyuki Yoda; Ryosuke Hanaoka; Hirotsugu Ide; Takeo Isozaki; Mizuho Matsunawa; Nobuyuki Yajima; Fumitaka Shiozawa; Yusuke Miwa; Masao Negishi; Tsuyoshi Kasama
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

7.  Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation.

Authors:  V C Emery; A V Cope; C A Sabin; A K Burroughs; K Rolles; T Lazzarotto; M P Landini; S Brojanac; J Wise; G T Maine
Journal:  J Infect Dis       Date:  2000-10-26       Impact factor: 5.226

8.  Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.

Authors:  F Rossini; E Terruzzi; S Cammarota; F Morini; M Fumagalli; L Verga; E Elli; M Verga; I Miccolis; M Parma; E M Pogliani
Journal:  Transpl Infect Dis       Date:  2005 Sep-Dec       Impact factor: 2.228

Review 9.  Pharmacologic immunosuppression.

Authors:  Neal R Barshes; Sarah E Goodpastor; John A Goss
Journal:  Front Biosci       Date:  2004-01-01

10.  Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus.

Authors:  Rodney Arcenas; Raymond H Widen
Journal:  BMC Microbiol       Date:  2002-07-23       Impact factor: 3.605
View more
  4 in total

Review 1.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain : Correlation with neurological deterioration and improvement upon antiviral treatment.

Authors:  N Goerig; S Semrau; B Frey; K Korn; B Fleckenstein; K Überla; A Dörfler; F Putz; U S Gaipl; R Fietkau
Journal:  Strahlenther Onkol       Date:  2016-05-31       Impact factor: 3.621

3.  Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain.

Authors:  Nicole L Goerig; Benjamin Frey; Klaus Korn; Bernhard Fleckenstein; Klaus Überla; Manuel A Schmidt; Arnd Dörfler; Tobias Engelhorn; Ilker Eyüpoglu; Paul F Rühle; Florian Putz; Sabine Semrau; Udo S Gaipl; Rainer Fietkau
Journal:  Neuro Oncol       Date:  2016-06-10       Impact factor: 12.300

Review 4.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.